Bromocriptine and Pasireotide interaction
Bromocriptine and Pasireotide: the Pasireotide prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Pasireotide (Signifor LAR) label · effective 2024-07-16
Bromocriptine: Consider bromocriptine dose reduction.
Bromocriptine Co-administration of SIGNIFOR LAR with bromocriptine may increase the blood levels of bromocriptine.
Dose reduction of bromocriptine may be necessary.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.